Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@OscarTahuahua Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1251032080881983489.png) @OscarTahuahua Oscar Tahuahua

Oscar Tahuahua posts on X about  the most. They currently have XXXXX followers and XX posts still getting attention that total X engagements in the last XX hours.

### Engagements: undefined [#](/creator/twitter::1251032080881983489/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1251032080881983489/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX +519%
- X Months XXXXXXX +3,369%
- X Year XXXXXXX +21,340%

### Mentions: undefined [#](/creator/twitter::1251032080881983489/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1251032080881983489/c:line/m:posts_active.svg)

- X Week XX +29%
- X Month XX +108%
- X Months XX +643%
- X Year XX +867%

### Followers: XXXXX [#](/creator/twitter::1251032080881983489/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1251032080881983489/c:line/m:followers.svg)

- X Week XXXXX +2%
- X Month XXXXX +12%
- X Months XXXXX +81%

### CreatorRank: undefined [#](/creator/twitter::1251032080881983489/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1251032080881983489/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1251032080881983489/influence)
---

**Social category influence**
[currencies](/list/currencies)  XXXX%

**Top accounts mentioned or mentioned by**
[@oncoalert](/creator/undefined) [@myesmo](/creator/undefined) [@dryakupergun](/creator/undefined) [@realbowtiedoc](/creator/undefined) [@drpatronus](/creator/undefined)
### Top Social Posts [#](/creator/twitter::1251032080881983489/posts)
---
Top posts by engagements in the last XX hours

"First study to investigate the mechanisms underlying recurrence after a pathologic response to neoadjuvant ipi plus nivo in stage III Melanoma Paired genomic and immune analyses show that relapse is not driven by classical immune escape mutations (B2M JAK1/2 HLA) but by a gradual loss of immune pressure 📴 The fight isn't over when the tumor disappears only when immune surveillance stays active 🕵♂ @OncoAlert"  
[X Link](https://x.com/OscarTahuahua/status/1976805935407308827) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-11T00:23Z 1415 followers, 3874 engagements


"HARMONi-6 In 1L squamous NSCLC ivonescimab + CTx PFS vs tislelizumab + CTx (11.1 vs XXX mo; HR 0.60) with consistent benefit across PD-L1 subgroups; OS immature; global trial pending. @OncoAlert @myESMO #ESMO25"  
[X Link](https://x.com/OscarTahuahua/status/1979923494704959960) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-19T14:52Z 1415 followers, 3471 engagements


"#ESMO25 FLAURA2 (Osimertinib + CTx as 1L) OS by prognostic factors ✅Global OS benefit: HR XXXX (p=0.02) ✅Benefit consistent across subgroups // statistically significant only in CNS metastases (HR 0.72) Supports combination therapy as 1L for EGFR mNSCLC"  
[X Link](https://x.com/OscarTahuahua/status/1979017849042612728) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-17T02:53Z 1415 followers, 5287 engagements


"#ESMO25 CheckMate 8HW In MSI-H/dMMR metastatic CRC nivo + ipi PFS (NR vs XXXX mo; HR 0.69) & with OS trend (HR 0.61) vs nivolumab alone with ORR (73% vs 61%) & good safety. Confirms dual ICI as SoC in this population Absolutely impressive results 😱 @OncoAlert @myESMO #ESMO25"  
[X Link](https://x.com/OscarTahuahua/status/1980162720176472270) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-20T06:42Z 1415 followers, 2708 engagements


"#ESMO25 NADINA In resectable stage III melanoma neoadjuvant nivo + ipi 2y EFS (77% vs XX% HR 0.40) & DMFS (83% vs XX% HR 0.43) vs adjuvant nivo. IFN PD-L1 & TMB emerged as key predictors; IFN-high TMB-high reached XXX% EFS. @OncoAlert @myESMO #ESMO25"  
[X Link](https://x.com/OscarTahuahua/status/1980166599702396952) [@OscarTahuahua](/creator/x/OscarTahuahua) 2025-10-20T06:58Z 1415 followers, 1981 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@OscarTahuahua Avatar @OscarTahuahua Oscar Tahuahua

Oscar Tahuahua posts on X about the most. They currently have XXXXX followers and XX posts still getting attention that total X engagements in the last XX hours.

Engagements: undefined #

Engagements Line Chart

  • X Week XXXXX -XX%
  • X Month XXXXXX +519%
  • X Months XXXXXXX +3,369%
  • X Year XXXXXXX +21,340%

Mentions: undefined #

Mentions Line Chart

  • X Week XX +29%
  • X Month XX +108%
  • X Months XX +643%
  • X Year XX +867%

Followers: XXXXX #

Followers Line Chart

  • X Week XXXXX +2%
  • X Month XXXXX +12%
  • X Months XXXXX +81%

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence #

Social category influence currencies XXXX%

Top accounts mentioned or mentioned by @oncoalert @myesmo @dryakupergun @realbowtiedoc @drpatronus

Top Social Posts #

Top posts by engagements in the last XX hours

"First study to investigate the mechanisms underlying recurrence after a pathologic response to neoadjuvant ipi plus nivo in stage III Melanoma Paired genomic and immune analyses show that relapse is not driven by classical immune escape mutations (B2M JAK1/2 HLA) but by a gradual loss of immune pressure 📴 The fight isn't over when the tumor disappears only when immune surveillance stays active 🕵♂ @OncoAlert"
X Link @OscarTahuahua 2025-10-11T00:23Z 1415 followers, 3874 engagements

"HARMONi-6 In 1L squamous NSCLC ivonescimab + CTx PFS vs tislelizumab + CTx (11.1 vs XXX mo; HR 0.60) with consistent benefit across PD-L1 subgroups; OS immature; global trial pending. @OncoAlert @myESMO #ESMO25"
X Link @OscarTahuahua 2025-10-19T14:52Z 1415 followers, 3471 engagements

"#ESMO25 FLAURA2 (Osimertinib + CTx as 1L) OS by prognostic factors ✅Global OS benefit: HR XXXX (p=0.02) ✅Benefit consistent across subgroups // statistically significant only in CNS metastases (HR 0.72) Supports combination therapy as 1L for EGFR mNSCLC"
X Link @OscarTahuahua 2025-10-17T02:53Z 1415 followers, 5287 engagements

"#ESMO25 CheckMate 8HW In MSI-H/dMMR metastatic CRC nivo + ipi PFS (NR vs XXXX mo; HR 0.69) & with OS trend (HR 0.61) vs nivolumab alone with ORR (73% vs 61%) & good safety. Confirms dual ICI as SoC in this population Absolutely impressive results 😱 @OncoAlert @myESMO #ESMO25"
X Link @OscarTahuahua 2025-10-20T06:42Z 1415 followers, 2708 engagements

"#ESMO25 NADINA In resectable stage III melanoma neoadjuvant nivo + ipi 2y EFS (77% vs XX% HR 0.40) & DMFS (83% vs XX% HR 0.43) vs adjuvant nivo. IFN PD-L1 & TMB emerged as key predictors; IFN-high TMB-high reached XXX% EFS. @OncoAlert @myESMO #ESMO25"
X Link @OscarTahuahua 2025-10-20T06:58Z 1415 followers, 1981 engagements

creator/x::OscarTahuahua
/creator/x::OscarTahuahua